Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Tax Provisions (2021 - 2024)

Prime Medicine's Tax Provisions history spans 4 years, with the latest figure at -$134000.0 for Q2 2024.

  • For Q2 2024, Tax Provisions fell 532.26% year-over-year to -$134000.0; the TTM value through Mar 2025 reached -$134000.0, down 335.09%, while the annual FY2023 figure was -$279000.0, 70.57% up from the prior year.
  • Tax Provisions reached -$134000.0 in Q2 2024 per PRME's latest filing, down from $134000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.4 million in Q4 2021 to a low of -$2.4 million in Q3 2021.
  • Average Tax Provisions over 4 years is -$201454.5, with a median of -$134000.0 recorded in 2024.
  • The largest YoY upside for Tax Provisions was 166.34% in 2024 against a maximum downside of 532.26% in 2024.
  • A 4-year view of Tax Provisions shows it stood at $1.4 million in 2021, then plummeted by 113.47% to -$186000.0 in 2022, then soared by 41.94% to -$108000.0 in 2023, then dropped by 24.07% to -$134000.0 in 2024.
  • Per Business Quant, the three most recent readings for PRME's Tax Provisions are -$134000.0 (Q2 2024), $134000.0 (Q1 2024), and -$108000.0 (Q3 2023).